Key result
Chronic heart failure with reduced ejection fraction was associated with a 37% excess 10-year mortality risk and a 2.4-fold greater loss of life expectancy compared to an age- and sex-matched control population.
Why the study?
Estimating survival aids care planning, but absolute survival projections can be hard to contextualize; the contribution of heart failure and comorbidities to lost actuarially predicted life expectancy was unclear.
Does chronic heart failure and its comorbidities reduce actuarially predicted life expectancy in adults with stable HFrEF compared to an age-sex matched control population?
Cohort (n=1,794)
Yes
Does chronic heart failure and its comorbidities reduce actuarially predicted life expectancy in adults with stable HFrEF compared to an age-sex matched control population?
Comorbidity accounts for the majority of lost life expectancy in people with heart failure, with women without comorbidity experiencing survival close to reference controls.
Supports life expectancy estimates for counseling in stable HFrEF; leaves open whether comorbidity interventions improve outcomes.
Background Estimating survival can aid care planning, but the use of absolute survival projections can be challenging for patients and clinicians to contextualize. We aimed to define how heart failure and its major comorbidities contribute to loss of actuarially predicted life expectancy. Methods We conducted an observational cohort study of 1794 adults with stable chronic heart failure and reduced left ventricular ejection fraction, recruited from cardiology outpatient departments of 4 United Kingdom (UK) hospitals. Data from an 11-year maximum (5-year median) follow-up period (999 deaths) was used to define how heart failure and its major comorbidities impact upon survival, relative to an age-sex matched control UK population, using a relative survival framework. Results After 10 years, mortality in the reference control population was 29%. In people with heart failure, this increased by an additional 37% (95% confidence interval 34-40%), equating to an additional 2.2-years of lost life, or a 2.4-fold (2.2-2.5) excess loss of life. This excess was greater in men than women (2.4 years [2.2-2.7] versus 1.6 years [1.2-2.0]; p<0.001). In patients without major comorbidity, men still experienced excess loss of life, whilst women experienced less and were non-significantly different from the reference population (1 year [0.6-1.5] versus 0.4 years [-0.3-1]; p<0.001). Accrual of comorbidity was associated with substantial increases in excess loss of life, particularly for chronic kidney and lung disease. Conclusions Comorbidity accounts for the majority of lost life expectancy in people with heart failure. Women, but not men, without comorbidity experience survival close to reference controls.
No takes yet. Share an insight, caveat, or question.
Drozd et al. (2020) conducted a cohort in stable chronic heart failure and reduced left ventricular ejection fraction (n=1,794). Chronic heart failure vs. Age-sex matched control UK population was evaluated on 10-year mortality (Excess risk 37%, 95% CI 33.6-40.5). Chronic heart failure with reduced ejection fraction was associated with a 37% excess 10-year mortality risk and a 2.4-fold greater loss of life expectancy compared to an age- and sex-matched control population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: